source
- Operational talent, not just science, will drive next biopharma breakthroughsThe piece points out that while breakthrough science, founders and venture funding are typical markers of progress, the real test is moving a promising therapy through GMP production, quality syste…
- Roche halts development of muscle-preserving obesity drug and returns program to ChugaiRoche announced it is ending work on the experimental muscle-building compound known as GYM329, which had been tested together with a GLP-1 based anti-obesity injection. The decision stops the ong…